{
    "organizations": [],
    "uuid": "9467a2a24e3ccc579d1018972d5e003a2a192c47",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-celsius-therapeutics-launches-with/brief-celsius-therapeutics-launches-with-65-million-in-series-a-financing-idUSASC0A275",
    "ord_in_thread": 0,
    "title": "BRIEF-Celsius Therapeutics Launches With $65 Million In Series A Financing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - CELSIUS THERAPEUTICS:\n* CELSIUS THERAPEUTICS LAUNCHES WITH $65 MILLION IN SERIES A FINANCING TO DEVELOP PRECISION THERAPEUTICS FOR PEOPLE WITH AUTOIMMUNE DISEASES AND CANCER\n* CELSIUS THERAPEUTICS - SERIES A FINANCING LED BY THIRD ROCK VENTURES WITH PARTICIPATION FROM GV (FORMERLY GOOGLE VENTURES) AND OTHER INVESTORS Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T18:39:00.000+03:00",
    "crawled": "2018-05-16T19:08:24.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "celsius",
        "therapeutic",
        "celsius",
        "therapeutic",
        "launch",
        "million",
        "series",
        "financing",
        "develop",
        "precision",
        "therapeutic",
        "people",
        "autoimmune",
        "disease",
        "cancer",
        "celsius",
        "therapeutic",
        "series",
        "financing",
        "led",
        "third",
        "rock",
        "venture",
        "participation",
        "gv",
        "formerly",
        "google",
        "venture",
        "investor",
        "source",
        "text",
        "eikon",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}